Ocugen (OCGN) Income towards Parent Company (2014 - 2026)
Ocugen's (OCGN) quarterly Income towards Parent Company came in at -$35.9 million in Q1 2026, down 131.98% YoY from $112.1 million in Q1 2025, and down 98.84% on a QoQ basis from -$18.0 million in Q4 2025.
Analysis
Ocugen (OCGN) Income towards Parent Company (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 13 years of Income towards Parent Company data on file, last reported at -$35.9 million in Q1 2026.
- Quarterly Income towards Parent Company fell 131.98% year-over-year to -$35.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$92.8 million (down 46.4% YoY) and the FY2025 annual result came in at -$198.0 million, down 14.43% from the prior year.
- Income towards Parent Company fell to -$35.9 million in Q1 2026, from -$18.0 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$13.0 million in Q3 2024 to a low of -$123.9 million in Q4 2023.
- A 5-year average of -$27.7 million and a median of -$21.0 million in 2024 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2023 — Income towards Parent Company slumped 464.92% — and 2024, when it jumped 88.75%.
- Tracing OCGN's Income towards Parent Company over 5 years: stood at -$21.9 million in 2022, then tumbled by 464.92% to -$123.9 million in 2023, then jumped by 88.75% to -$13.9 million in 2024, then declined by 29.36% to -$18.0 million in 2025, then slumped by 98.84% to -$35.9 million in 2026.
- The last three Income towards Parent Company figures came in at -$35.9 million (Q1 2026), -$18.0 million (Q4 2025), and -$18.7 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Ocugen | 458.91 Mn | 358.81 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -20.52 Mn |
| Mar 31, 2026 | -19.03 Mn |
| Dec 31, 2025 | -18.21 Mn |
| Sep 30, 2025 | -18.73 Mn |
| Jun 30, 2025 | -14.85 Mn |
| Mar 31, 2025 | -15.42 Mn |
| Dec 31, 2024 | -13.98 Mn |
| Sep 30, 2024 | -12.97 Mn |
| Jun 30, 2024 | -15.28 Mn |
| Mar 31, 2024 | -11.91 Mn |
| Dec 31, 2023 | -11.53 Mn |
| Sep 30, 2023 | -12.43 Mn |
| Jun 30, 2023 | -23.54 Mn |
| Mar 31, 2023 | -18.04 Mn |
| Dec 31, 2022 | -21.94 Mn |
| Sep 30, 2022 | -21.92 Mn |
| Jun 30, 2022 | -21.58 Mn |
| Mar 31, 2022 | -19.03 Mn |
| Dec 31, 2021 | -14.58 Mn |
| Sep 30, 2021 | -10.76 Mn |